Abelacimab

Generic Name: Abelacimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2098724-83-3

Unique Ingredient Identifier: KX1N4TV7UY

Background: Abelacimab is under investigation in clinical trial NCT04755283 (Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

What Now for Factor XI Inhibitors in AF?

Factor XI inhibition, once promising for reducing thrombotic risk without significant bleeding, faced a setback with the OCEANIC-AF trial's early stoppage due to asundexian's inferiority to apixaban in preventing ischemic stroke. Experts suggest the dose may have been insufficient and await results from ongoing trials to fully assess factor XI inhibitors' potential.

pharmacytimes.com

2 months ago

Reduced Bleeding With Abelacimab Could Transform Atrial Fibrillation Treatment

Christian Ruff, MD, MPH, presented results from the AZALEA-TIMI 71 trial, showing abelacimab (Anthos) significantly reduced bleeding in high-risk patients with atrial fibrillation and atherosclerotic cardiovascular disease compared to rivaroxaban. Abelacimab targets factor 11 in the blood clotting cascade, reducing bad clots without inhibiting healing clots, leading to a 60-70% reduction in bleeding. Future research includes the LILAC-TIMI 76 trial to establish abelacimab's efficacy in reducing stroke in high-risk patients.

Related Clinical Trials:

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

Study to EvaLuate the EffIcacy and Safety of AbeLacimab in High-risk Patients with Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral AntiCoagulation (LILAC-TIMI 76)